613 related articles for article (PubMed ID: 23261355)
21. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
[TBL] [Abstract][Full Text] [Related]
22. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
23. [The natural history of cervical intraepithelial neoplasia I and the clinical significance of p16(INK4a) protein as a marker of progression in cervical intraepithelial neoplasia I].
Wang R; Li X; Qian M; Niu J; You Z
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):210-5. PubMed ID: 26268412
[TBL] [Abstract][Full Text] [Related]
24. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
[TBL] [Abstract][Full Text] [Related]
25. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
26. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
27. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.
Bergeron C; Giorgi-Rossi P; Cas F; Schiboni ML; Ghiringhello B; Dalla Palma P; Minucci D; Rosso S; Zorzi M; Naldoni C; Segnan N; Confortini M; Ronco G
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25568167
[TBL] [Abstract][Full Text] [Related]
28. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
29. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
[TBL] [Abstract][Full Text] [Related]
30. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.
Benevolo M; Ronco G; Mancuso P; Carozzi F; De Marco L; Allia E; Bisanzi S; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Viti J; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Bonvicini L; Venturelli F; Wentzensen N; Giorgi Rossi P;
EBioMedicine; 2024 Jun; 104():105149. PubMed ID: 38759278
[TBL] [Abstract][Full Text] [Related]
31. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
33. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
34. Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
Gilbert L; Ratnam S; Jang D; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wadhawan A; Costescu D; Elit L; Wang P; Zahariadis G; Chernesky M
Cancer Biomark; 2022; 34(3):347-358. PubMed ID: 35001877
[TBL] [Abstract][Full Text] [Related]
35. Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year prospective study.
White CM; Bakhiet S; Bates M; Ruttle C; Pilkington LJ; Keegan H; O'Toole SA; Sharp L; O'Kelly R; Tewari P; Flannelly G; Martin CM; O'Leary JJ;
Cancer Epidemiol; 2020 Oct; 68():101793. PubMed ID: 32841926
[TBL] [Abstract][Full Text] [Related]
36. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
Zhang G; Yang B; Abdul-Karim FW
Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
38. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
